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ECMO in cardiac arrest
and cardiogenic shock
Cardiogenic shock and cardiac arrest are
life-threatening emergencies with a high
mortality rate despite numerous eﬀorts
in diagnosis and therapy. For a long
time medical therapy – at the forefront
with catecholamines, vasodilators and
others – and mechanical ventilation, if
necessary, were the standard of care for
cardiogenic shock. Oxygen supply and
perfusion are critically reduced during
shock and arrest, and both are physical
processes that are in principle amenable
to (temporary) extracorporeal mechan-
ical support. Early pioneering work
to prove this principle was performed
in animals as early as 1937 [1] and in
humans 20–30 years later [2, 3]. With
the seminal paper by Hill and coworkers
[4], extracorporeal membrane oxygena-
tion (ECMO), which can provide blood
ﬂow support and extracorporeal gas ex-
change at the same time, was introduced
into the clinic. Since then, technical
improvements have contributed to the
current worldwide use of ECMO for
severe respiratory and cardiorespiratory
failure refractory tomedical therapy. Re-
cently, there has been some discussion
on initiating mechanical support even
earlier, with the intention to avoid mul-
tiorgan failure associated with excessive
catecholamine doses and/or aggressive
ventilator settings. By analogy with
the concept of veno-venous ECMO and
lung-protective ventilation for treatment
of acute respiratory distress syndrome,
the goal of mechanical support in car-
diogenic shock is myocardial rest while
protecting end organ perfusion.
In the following, we review ECMO
support in the context of cardiogenic
shock and refractory cardiac arrest, with
a special focus on technical aspects of
veno-arterial ECMO. Of note, the fol-
lowing statements are primarily true for
percutaneous ECMO with femoral can-
nulation and may not necessarily be di-
rectly transferable to central or upper-
body cannulation.
Cardiogenic shock and cardiac
arrest
Cardiogenic shock is the main cause of
early mortality in patients with acute
myocardial infarction [5]. Other condi-
tions leading to shock comprise acutely
decompensated chronic heart failure,
decompensated valvular heart disease,
myocarditis, Takotsubo syndrome, acute
pulmonary embolism, acute allograft
failure, incessant arrhythmia, peripar-
tum cardiomyopathy [6], and others [7].
During cardiogenic shock not only the
heart itself suﬀers from pump failure,
but even more end organs such as the
brain, kidney, liver, and gut are at risk
due to insuﬃcient perfusion (multior-
gan dysfunction syndrome) [8], and the
rate of congestion-associated pneumonia
increases. Beyond blood pressure and
heart rate as classic shockmarkers, serum
lactate, central venous oxygenation, liver
enzyme levels, and urine output are sur-
rogate markers of circulatory failure and
multiorgan dysfunction [9]. Reduced
coronary perfusion further decreases
cardiac output, and multiorgan dysfunc-
tion/failure is further complicated by
metabolic acidosis and acute coagulopa-
thy. All of these conditions aggravate
each other in a fatal vicious circle [8, 9].
Out-of-hospitalcardiacarrest(OHCA)
occurs with an estimated incidence of
500,000 per year in Europe [10, 11],
with two thirds having a primary car-
diac cause [12]. Mortality after OHCA
remains high despite interventional ther-
apy and modern intensive care. Only
10–15% of those who arrive at the nor-
mal hospital survive [13, 14], of whom
about 50–80%have a favorable neurolog-
ical prognosis [15, 16]. In this context,
immediate bystander CPR and area-
wide availability of automated external
deﬁbrillators are essential to increase
survival and prognosis. The ﬁrst elec-
tric shock should be applied as early
as possible [17] to minimize the time
of hypoperfusion, associated LV pump
failure, and consecutive development of
shock [18]. After return of spontaneous
circulation (ROSC), the patient needs to
be transferred to an experienced center,
which holds all required diagnostic and
therapeutic tools [19]. In clinical routine,







IABP Intra-aortic balloon pump
LV Left ventricle
LVAD Left ventricular assist device
OHCA Out-of-hospital cardiac arrest
ROSC Return of spontaneous circulation
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Table 1 Strategies ofmechanical circulatory support
Strategy Indication (examples) Principle Goal
Bridge-to-recovery Acute heart failure
(myocarditis, acute
myocardial infarction)
Stabilize systemic circulation, ensure end organ perfusion and reduce









Terminal heart failure Stabilize systemic circulation, ensure end organ perfusion until LVAD
implantation
LVAD
Bridge-to-surgery Acute pulmonary embolism
with shock (and contraindi-
cation for ﬁbrinolysis)
Reduce preload and stabilize systemic circulation until emergent em-
bolectomy
Embolectomy
Bridge-to-decision Extracorporeal CPR Stabilize systemic circulation, ensure end organ perfusion until (neuro-




ECMO implantation at the referral center by the ECMO team and trans-
port to the tertiary center for further therapy
Transfer
CPR cardiopulmonary resuscitation, ECMO extracorporeal membrane oxygenation, LVAD left ventricular assist device
decide on the outcome, and guidelines
recommend cardiac catheterization in
most cases early after OHCA [20, 21].
Therefore, primary admission to a ter-
tiary center should be preferred over
admission to a regional hospital and
secondary transfer to a tertiary center,
when progression of shock has already
occurred.
The majority of patients after OHCA
develop post-cardiac arrest syndrome
[22, 23] in a vicious circle: Cardiac ar-
rest leads to ischemia of the myocardium
and end organs, which results in adverse
metabolism, acidosis, and vasoplegia.
The hypoperfused heart is not able to
respond to the circulatory needs, which
in turn aggravates peripheral ischemia
[24]. Therefore, restoration of systemic
perfusion is essential – particularly in the
immediate and early phase after ROSC
– in order to limit multiorgan dysfunc-
tion [25], which can also be considered
a “whole-body reperfusion syndrome.”
In this context, complete cardiac revas-
cularization is recommended [12, 26],
but care of other end organs such as
the brain, intestine, liver, and kidneys is
equally important [23].
As outlined, cardiogenic shock and
cardiac arrest share many pathophysio-
logical features and evoke many similar
responses. Thus, itwasnot surprisingbut
very important to prove that the progno-
sis of both conditions is equally adverse:
In a recent study of 250 consecutive pa-
tients from Denmark, 130 were admit-
ted to a tertiary center with cardiogenic
shock, while 118 had OHCA. Interest-
ingly, both groups had the same dismal
outcomewith60%1-weekmortality [27].
This underlines the urgent need for novel
therapeutic strategies for patients with




used for stabilizationof patientswith car-
diogenic shock. Inotropes such as dobu-
tamine are given with the intention to
increase cardiac output by their posi-
tive inotropic and chronotropic function.
In contrast, vasopressors such as nore-
pinephrine are administered for increas-
ing blood pressure by vasoconstriction
and indirect eﬀects such as increased
preload. Epinephrine shares features of
both drug classes. However, inotropic
drugs increase myocardial oxygen con-
sumption, heart rate, arrhythmogenicity,
and inﬂammation in the already diseased
heart [28]. Beta1-adrenoceptor agonists
have been associated with energy deple-
tion, oxidative stress, and adverse out-
come in acute heart failure [29]. Va-
sopressors increase myocardial afterload
and potentially impair peripheral tissue
perfusion. Thus, from a pathophysio-
logical perspective, inotropes as well as
vasopressors are associated with adverse
eﬀects on the heart and other end organs
while these organs should recover. Con-
sistently, current guidelines recommend
catecholamines as a short-term bridge in
the acute situation (only class IIb, level
of evidence C), but clearly mention the
disadvantages of such drugs, also in light
of the paucity of clinical studies demon-
strating a survival beneﬁt [25, 30, 31].
In clinical routine, catecholamines are
often “eﬀective” in terms of increasing
blood pressure, but linked to impaired
microcirculation and multiorgan failure,
and thus not suﬃcient for sustained and
harmless stabilizationof patients with se-
vere cardiogenic shock and resuscitation.
In this context, beta-blockers and cal-
cium antagonists taken by the patient
before arrest might further contribute to
the limited eﬃcacy of catecholamines.
Therefore, it is increasingly being dis-
cussed to initiate mechanical circulatory
support as a powerful tool for bridging
earlier and more frequently, in order to
improve the prognosis of patients with
severe cardiogenic shock or refractory
arrest [32]. However, this trend is based
on data from many registries and retro-
spective/observational studies, while evi-
dence fromprospective randomized con-
trolled studies is lacking.
Mechanical circulatory support
Several modes and devices of mechani-
cal support are currently available [32],
of which each has its own features and
advantages.
The intra-aortic balloonpump (IABP)
consists of a catheter-mounted balloon
that inﬂates during diastole and deﬂates
during systole in the descending tho-
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racic aorta. By this, coronary perfu-
sion should be enhanced during diastole,
while afterload should be decreased dur-
ing systole when the left ventricle (LV)
ejects. Notwithstanding the attractive
pathophysiological principle, augmenta-
tion by IABP depends on LV output, and
the potential of support decreases with
lower LV output. Several studies have
demonstrated that IABP support is not
favorable in infarct-related cardiogenic
shock [33, 34]. Therefore, current guide-
lines have retracted the recommendation
of IABP use [31].
TheTandemHeart®consists of a pump
and two cannulas, of which one is in-
serted via venous access and transseptal
approach into the left atrium (LA),
and the other one via arterial access
into the femoral artery. By this, the
TandemHeart® introduces a right-to-
left shunt, reduces LV preload by LA
drainage, but increases afterload by ret-
rograde ﬂow support toward the aorta.
The TandemHeart® is not widely used
in Europe and requires experienced
transseptal cannula placement, which is
assumed to harbor considerable risk in
the acute situation.
Transaorticmicroaxialpumps(Impel-
la®, Heartmate PHP®) are introduced via
arterial access through the aorta across
the aortic valve into the LV. These de-
vices directly unload the LV, transport
the drained volume inside of the pump
toward the aorta and eject into the aor-
tic root. This elegant approach, which
follows the physiological blood ﬂow di-
rection, is comprehensively described in
the same issue of this journal (Schäfer A,
Bauersachs J, doi: 10.1007/s00059-016-
4512-7). However, microaxial pumps do
not oﬀer gas exchange or temperature
control.
Probably, the most often used form of
mechanical circulatory support today is
ECMO.Originating fromcardiac surgery
and initially developed for temporary
lung replacement, ECMOsupport is now
broadly established for cardiorespiratory
support [35]. Notwithstanding its enor-
mous support potential, ECMO has sev-
eral special features and harbors certain
speciﬁc risks, whichwill be reviewedhere
(see next sections).
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ECMO in cardiac arrest and cardiogenic shock
Abstract
Cardiogenic shock is an acute emergency,
which is classically managed by medical
support with inotropes or vasopressors and
frequently requires invasive ventilation.
However, both catecholamines and ventila-
tion are associatedwith a worse prognosis,
and many patients deteriorate despite all
eﬀorts. Mechanical circulatory support is
increasingly considered to allow for recovery
or to bridge until making a decision or deﬁnite
treatment. Of all devices, extracorporeal
membrane oxygenation (ECMO) is the most
widely used. Here we review features and
strategical considerations for the use of ECMO
in cardiogenic shock and cardiac arrest.
Keywords
Cardiogenic shock · Cardiac arrest · Sudden
cardiac death · Cardiopulmonary resus-
citation · ECMO · Mechanical circulatory
support · Microaxial pump · Extracorporeal
resuscitation
ECMO bei Herz-Kreislauf-Stillstand und kardiogenem Schock
Zusammenfassung
Der kardiogene Schock ist ein akut lebens-
bedrohlicher Notfall, der klassischerweise
medikamentös (u. a. Inotropika und ggf.
Vasopressoren) behandelt wird und häuﬁg
eine invasive Beatmung erfordert. Katecho-
lamine und Beatmung sind jedoch mit einer
ungünstigen Prognose assoziiert, und viele
Patienten sind mit konservativen Maßnah-
men nicht zu stabilisieren. Mechanische
Kreislaufunterstützung wird immer öfter her-
angezogen, um den Kreislauf zu stabilisieren,
dem erkrankten Herzen Zeit zur Erholung zu
verschaﬀen oder eine Überbrückung bis zur
deﬁnitiven Therapie zu etablieren. Das aktuell
weltweit am häuﬁgsten eingesetzte System
zur mechanischen Kreislaufunterstützung in
diesemZusammenhang ist die extrakorporale
Membranoxygenierung (ECMO). In der
vorliegenden Übersicht fassen die Autoren
die speziellen Eigenschaften dieses Systems
sowie strategischeÜberlegungen im Kontext
des kardiogenen Schocks und des Herz-
Kreislauf-Stillstands zusammen.
Schlüsselwörter
Kardiogener Schock · Herz-Kreislauf-Still-
stand · Plötzlicher Herztod · Wiederbelebung ·
ECMO · Mechanische Kreislaufunterstüt-
zung · Mikroaxialpumpe · Extrakorporale
Reanimation
In general, mechanical support can be
used with diﬀerent strategies (. Table 1).
In patients with severe cardiogenic
shock from myocardial infarction or
myocarditis, mechanical support is rou-
tinely employed in a bridge-to-recovery
approach. In the case of acute de-
compensated chronic heart failure, the
potential for recovery may be limited,
which sometimes results in a bridge-
to-destination approach. In resuscitated
patients, a bridge-to-decision strategy
is usually required, as further therapies
such as LVAD surgery, ICD implantation
etc. are postponed until awakening of
the patient allows for estimating neuro-
logical recovery and eligibility.
Veno-arterial ECMO
Technical aspects
ECMO is a modiﬁed form of cardiopul-
monary bypass [36], and has undergone
a dramatic technical evolution since the
widely known publication by Hill and
coworkers in 1972 [4]. In principle,
ECMO drains venous blood through
a cannula and tubing and returns it
via another tubing and cannula into the
body, both driven by a rotor unit. During
ECMO passage the blood becomes oxy-
genated, decarboxylated, and warmed
in an extracorporeal gas exchange unit.
In nonsurgical application in adults,
peripheral cannulation of the femoral
and/or jugular vessels is the standard
technique, usually with 21–25 French
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Table 2 Technical features of VA-ECMO
Implantation Cannulation of femoral artery (15–19 Fr) and vein (21–15 Fr) with modi-
ﬁed Seldinger’s technique takes about 10min until circuit starts
Mobility Inter- and intrahospital transfer, up to air-bridge (ﬂight transfer)
Hemodynamic
eﬀect
Increased systemic perfusion by retrograde ﬂow support
Preload reduction
Afterload increase
Flow rates Up to 7 l/min, depending on cannulas and rotor/oxygenator
Gas exchange Highly eﬃcient oxygenation and decarboxylation of reinfused blood
Contraindications Ethical considerations, patient’s will
No perspective of a bridging strategy
Severe peripheral artery disease (iliac)
(Severe) aortic regurgitation
Aortic dissection
Left ventricular thrombus (relative)










Fr French, VA-ECMO veno-arterial extracorporeal membrane oxygenation
draining and 15–19 French returning
cannulas (. Table 2). Veno-venous (VV)
ECMO drains from and returns to the
right atrium. It is used for replacement
of lung function, typically during acute
respiratory distress syndrome, and is not
further discussed here.
In contrast, veno-arterial (VA)ECMO
drains blood from the right atrium and
returns to the arterial system, typically
to the iliac arteries toward the aorta
(. Fig. 1). By this, VA-ECMO reduces
preload and increases aortic ﬂow and
end organ perfusion [36]. With arterial
cannulation, placement of a dedicated
sheath for antegrade perfusion of the
cannulated leg (. Fig. 1) is recommended
to prevent leg ischemia [37], which is
standard in many centers.
Agreat advantageofVA-ECMOis that
cannulationmaybeperformednearly ev-
erywhere, as the system and all parts are
transportable. Thus, an unstable patient
can receive ECMO support in the emer-
gency room, on theward, in the catheter-
ization laboratory, the operating theater,
or even in the ﬁeld [38, 39]. In contrast
to other support systems, ﬂuoroscopy
or echocardiography guidance is – al-
beit helpful – not required for successful
implantation. Once ECMO is running,
the patient can be transferred with the
whole unit, which is another advantage
over other systems. Therefore ECMO is
frequently used for transport of unsta-
ble patients by car, helicopter, or even by
plane as an air-bridge [40].
VA-ECMO establishes a massive
right-to-left shunt by draining venous
blood and returning it to the iliac artery.
This ﬂow support, which can reach
7 l/min with large cannulas and con-
temporary rotors, results in a signiﬁcant
increase inbloodpressure as long as there
is enough vascular resistance (pressure =
ﬂow × resistance). The massive venous
drainage eﬀectively reduces preload and
thus leads to venous decongestion. Arte-
rial reinfusion to the systemic circulation
strongly enhances perfusion of end or-
gans and is therefore attractive during
severe cardiorespiratory failure or re-
suscitation. Of note, at the same time
retrograde ﬂow support increases LV
afterload (see next section).
Contraindications and
complications
Notwithstanding the fast set-up of the
system and the eﬃcient hemodynamic
support, VA-ECMO has contraindica-
tions and harbors a signiﬁcant risk of
complications (. Table 2). Most con-
traindications are relative owing to the
lifesaving nature of ECMO support,
which in turn underlines that ECMO
should only be initiated when ethical
aspects or the patient’s wish do not pre-
clude mechanical support. Uncontrolled
bleeding is a contraindication, as ECMO
requires heparin for anticoagulation at
least for longer support. In selected
patients, however, this contraindication
is relative, if ECMO is the only strategy
to save the life of the patient. There are
indeed centers that run ECMO support
in high-risk patients without any anti-
coagulation (oﬀ-label) for a limited time
(such as in severe trauma [41] or diﬀuse
alveolar hemorrhage [42]). A nearly ab-
solute contraindication is severe aortic
regurgitation: The retrograde ﬂow sup-
port of VA-ECMO would cause severe
LV distension and pulmonary edema.
VA-ECMO results in LV distension even
in patients with moderate aortic regur-
gitation [43]. Further contraindications
are listed in . Table 2.
ECMO support is an invasive pro-
cedure with profound changes of body
oxygenation and circulation, and inher-
ently associated with potentially severe
complications [37, 44]. Among these
are vascular complications, leg ischemia,
bleeding, hyperﬁbrinolysis, stroke, and
air embolism (. Table 2). These are an-
ticipated and in most cases eﬀectively
controlled in tertiary centers. This em-
phasizes that initiation, maintenance,
weaning, and removal of ECMO re-
quires a strong theoretical and practical
expertise and should be performed in
high-volume centers only.
Pathophysiology: watershed
The retrograde ECMO output meets the
antegrade LV output at a zone called
the “watershed” [36, 45, 46]. In most
cases the watershed occurs somewhere
between the aortic root and the di-
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Fig. 18 Veno-arterial (VA) ECMO. VA-ECMO
drains venous blood (blue) from the right atrium
and returns an equal volume after reoxygena-
tion anddecarboxylation (red) to the iliac artery
toward the aorta. Note the positionof the drain-
ing venous cannula tip in themid right atrium.
Femoral arterial cannulation requires an extra
sheath for antegrade perfusion of the leg (in-
set). (Modiﬁed fromNapp&Bauersachs [49]; ©
L. C. Napp, J. Bauersachs 2016. This publication
is an open access publication, available on inte-
chopen.com)
aphragm (. Fig. 2), depending on the
native output of the heart: The higher the
LV output relative to ECMO output, the
more distal the watershed [46]. Since
the output of most ECMO devices is
nonpulsatile, pulse pressure measured
at the right radial artery serves as an
estimate of LV output [46]. For example,
a blood pressure of 80/70 mmHg at an
ECMOﬂowof 4.5 l/min suggests awater-
shed in the aortic root, whereas a blood
pressure of 140/70 mmHg at the same
ECMO ﬂow suggests a watershed in the
descending thoracic aorta. Blood from
the ECMO is usually well oxygenated;
however, oxygenation of blood from the
LV depends on the respiratory function
of the lung. Therefore the position of
the watershed is critical for oxygena-
tion. Aortic root oxygenation cannot be
continuously measured with standard
equipment. If the watershed is located
in the ascending aorta and blood from
the LV has an oxygen saturation of, e. g.,
Fig. 28 Watershedphenomenonduring VA-ECMO. Computed tomography.Antegrade blood ﬂow
(low contrast) from the heart competeswith retrograde blood ﬂow (high contrast) from the ECMO in
the aorta, resulting in awatershedphenomenon (arrowhead).Here computed tomography of a pa-
tientwith pulmonary embolismand reduced cardiac output demonstrates a rather proximal water-
shed, leadingtoperfusionoftherightcarotidarterywith“heartblood”(dark)andthe leftcarotidartery
with“ECMOblood” (bright, arrows). Upper panel: sagittalobliquemaximumintensityprojection (MIP);
middle panel: coronal obliqueMIP; lower panel: transverse plane. (FromNapp et al. [36]; © L. C. Napp,
C.Kühn,M.M.Hoeperet al. 2015. This publication is anopenaccesspublication, availableonspringer-
link.com)
56% during lung failure, then the heart
itself may be perfused for hours or days
with an extremely insuﬃcient oxygen
saturation from the lungs in the presence
of suﬃcient oxygenation of all other or-
gans from the ECMO. In this context,
the extreme form of dismal circulation is
the “two-circulation-syndrome” [47]: If
the venous cannula is incorrectly placed
in the inferior caval vein, so that only
blood from the lower body is drained,
blood from the upper body goes through
the lungs to the ascending aorta. Then
venous drainage from and the perfusion
of the upper body are both disconnected
from that of the lower body. This results
in a “Harlequin”-like appearance of the
patient, with upper-body hypoxia and
lower-body hyperoxia.
As outlined, circulation and oxy-
genation are overall subject to profound
changes during VA-ECMO. Therefore
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Table 3 Monitoring of patients on VA-ECMOa
Parameter Reason/surrogate
Hemodynamics
PA catheter: Mean PA pressure, PC wedge pres-
sure
Eﬃcacy of preload reduction
Central venous pressure Eﬃcacy of preload reduction
Right radial pulsatility LV output
Right radial mean blood pressure Perfusion pressure
Consider CCO catheterb LV output
Central venous oxygen saturation Systemic circulation
Urine output Renal perfusion and function
Lab: liver enzymes Venous decongestion
Respiratory support
Right radial blood gases Brain oxygenation, decarboxylation
Lactate End organ ischemia
Transcutaneous continuous near-infrared spec-
troscopy
Tissue oxygenation (independent of pulsatil-
ity)
Pulse oximetry (right hand ﬁnger or ear) Tissue oxygenation (largely dependent of
pulsatility)
Acral perfusion (clinical) Tissue perfusion







Chest X-Ray Pulmonary edema, pneumothorax
Pleural sonography Pleural eﬀusion
Coagulation
D-dimer, ﬁbrinogen, platelet count Hyperﬁbrinolysis
Free hemoglobin, LDH Hemolysis
Activated clotting time (POCT) Anticoagulation
Blood cell count Anemia, thrombopenia
Leg perfusion
Clinical perfusion assessment Ischemia of the cannulated leg
General critical care monitoring
CCO continuous cardiac output, LDH lactate dehydrogenase, LV left ventricle, PA pulmonary artery,
PC pulmonary capillary, POCT point of care testing
aPeripheral femoro-femoral cannulation
bClassic thermodilution is not reliable owing to right atrial drainage
multiple parameters have to be moni-
tored in a patient on VA-ECMO at the
same time (. Table 3; [48]).
Triple cannulation
VA-ECMO delivers powerful circulatory
and respiratory support (. Table 2). Car-
bon dioxide elimination by the ECMO
is nearly always suﬃcient, thus hyper-
capnia is nearly never a problem in pa-
tients on ECMO support – in contrast to
(diﬀerential) hypoxia. As outlined ear-
lier, the high oxygen content of ECMO
output reaches only organs below the
watershed. Thus, under normal condi-
tions the lower extremities, gut, kidneys,
liver etc. are well oxygenated during VA-
ECMO support. An additional eﬀect on
organ oxygenation results from a higher
amount of oxygen delivered to the lower
body and an associated higher venous
backﬂow oxygen: Depending on oxy-
genation settings, ECMO outﬂow pO2
usually equals at least 200–300 mmHg,
compared with 50–100 mmHg in arte-
rial blood oxygenated in the lungs of
a standard ventilated shock patient. This
results in a higher total oxygen delivery
to the body, which may have an eﬀect
also on organs perfused by LV blood, yet
the relevance of this eﬀect is unclear to
date.
However, in some patients on VA-
ECMO support secondary lung failure
develops. This is a dangerous situation:
Depending on the watershed position,
all organs perfused by blood from the
heart are prone to severe ischemia in the
presence of ECMO support, in particu-
lar the heart and brain. If lung failure
is due to pulmonary edema, ultraﬁltra-
tion and active LV unloading (see later)
are suﬃcient to achieve decongestion.
However, in many patients with lung
failure on VA-ECMO support, the prob-
lemresults fromanARDS-like condition,
which cannot be or should not be eﬀec-
tively solved by aggressive ventilation or
decongestion. Inthesepatientsanelegant
and very eﬀective treatment is upgrading
the ECMO circuit to a triple-cannulated
ECMO, with one venous-draining, one
arterial-supplying, and one venous-sup-
plying cannula (“VAV-ECMO”, . Fig. 3;
[36, 49]). In addition to the VA cir-
cuit, the additional venous cannula adds
preoxygenated blood to the lungs and
thereby establishes a “VV component.”
This ensures suﬃcient oxygen content of
blood ejected by the heart and allows
for lung protective ventilation. Of note,
VAV-ECMOrequires suﬃcient RV func-
tion, otherwise it may be necessary to re-
locate the venous-supplying cannula into
the pulmonary artery [49] for bypassing
the RV. Retrospective studies suggest ef-
ﬁcacy of VAV cannulation for rescue of
body oxygenation and recovery of lung
failure [50–52], but prospective studies




During acute heart failure, the diseased
LV has impaired ability to eject, and
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Fig. 38 Veno-arterial-venous (VAV) ECMO.
VAV-ECMOdrains venous blood (blue) from the
right atrium and returns balanced volumes of
blood after reoxygenation anddecarboxylation
(red) to the iliac artery toward the aorta and to
the right atrium toward the pulmonary circu-
lation. For this purpose, the ECMOoutﬂow is
divided by a Y-connector. Flow through the re-
turning cannulae is balancedwith an adjustable
clamp andmonitoredwith a separate ﬂow sen-
sor on the upper return cannula. (Modiﬁed from
Napp&Bauersachs [49]; © L. C. Napp, J. Bauer-
sachs 2016. This publication is an openaccess
publication, available on intechopen.com)
stroke work andmyocardial oxygen con-
sumption are increased [30, 53]. When
bridge-to-recovery is the therapeutic
goal (e. g., myocarditis or myocardial
infarction), stroke work and myocardial
oxygen consumption have to be reduced
to facilitate regeneration. However,
notwithstanding the immediate massive
hemodynamic and respiratory support
and the reduction of preload, VA-ECMO
increases LV afterload [53–57]. Thismay
result in increased LV ﬁlling pressures,
wall stress, and severe pulmonary con-
gestion despite reduction of preload.
Moreover, ECMO is often ascribed
a positive eﬀect on coronary perfusion;
however, human data are lacking and
data from animal studies are conﬂicting
[58, 59]. From a pathophysiological
perspective, a high LV pressure during
diastole impairs coronary perfusion by
reducing the transcoronary perfusion
Fig. 48 VA-ECMO and active LV unloading by
using an Impella®microaxial pump. In addition
and in contrast to VA-ECMO,which delivers ret-
rograde ﬂow support to the aorta, the Impella®
pumpdrains the LV and supplies the blood to
the ascending aorta. This “unloads” the LV and
facilitatesmyocardial recovery andpulmonary
decongestion. (Modiﬁed fromNapp&Bauer-
sachs [49]; © L. C. Napp, J. Bauersachs 2016.This
publication is an open access publication, avail-
able on intechopen.com)
gradient. In patients with extremely low
systolic LV function and in all patients
with ongoing arrest, VA-ECMO support
results in a functionally closed aortic
valve without relevant transaortic blood
ﬂow. This potentially results in severe LV
distension [54] and pulmonary conges-
tion in the presence of suﬃcient systemic
circulation.
Thus, LV unloading, prevention of LV
distension, reduction of myocardial wall
stress, and enhancementof coronaryper-
fusion are important goals during me-
chanical circulatory support for bridge-
to-recovery. Unloading (= “venting”)
can be achieved by diﬀerent methods.
One way is venting through the atrial
septum, either by atrioseptostomy [60,
61] or placement of an additional drain-
ing cannula through the atrial septum
[62], both of which are potentially haz-
ardous [61] particularly in the already
critically ill patient. Another possibil-
ity is transvalvular unloading across the
aortic valve, which has already been per-
formed inanexperimental approachwith
a transvalvular coronary catheter con-
nected to the venous draining ECMO
cannula [63]. However, simple drain-
ing of the LV has no direct eﬀect on
coronaryperfusionanddoesnot increase
antegrade transaortic blood ﬂow. There-
fore pumps have been developed that are
percutaneously inserted, drain the LV,
and eject into the ascending aorta. Their
ﬁrst use (Hemopump®) was published
as early as in 1990 [64], but the clin-
ical breakthrough took nearly 20 years
to occur, mainly attributed to technical
improvement of the device. Today, the
only transvalvular microaxial pump ap-
proved in the United States and Europe
is the Impella® device (Abiomed, Dan-
vers, USA), which is the current device of
choice of most centers for active LV un-
loading, also combined with VA-ECMO
(. Fig. 4).
The frequency of the combined use of
ECMO and Impella® varies greatly be-
tween centers. Of note, it is unclear to
datewhichpatientshaveabeneﬁtofaddi-
tional Impella® support in parallel toVA-
ECMO. There are two published stud-
ies reporting combined support [65, 66].
Their data point to a beneﬁt of dual sup-
port, but further studies are unequivo-
callyneeded. . Fig. 5showsaproposal for
the management of VA-ECMO and po-
tential unloading, based on pathophysi-
ological considerations and clinical prac-
tice in our center. In general, the lower
systolic LV function is in a given patient,
the sooner active LV unloading should
be considered.
VA-ECMO for cardiogenic shock
Despite the broad use of ECMO in expe-
rienced centers, data from larger studies
are limited. Most studies are retrospec-
tive series or registry studies. Some years
ago, IABP was used in many countries
almost routinely for patients with severe
cardiogenic shock, but later on random-
ized studies demonstrated the noneﬀec-
tiveness of routine IABP support [33].
With this in mind, the decision for or
against mechanical support and the de-





















cision for a speciﬁc device should take
into account several diﬀerent factors such
as RV and LV function, valve status,
and lung function. The available devices
(ECMO, Impella®, TandemHeart®) each
have unique features, and there is no
uniform device covering all types of car-
diogenic shock. This is one of the ma-
jor limitations of nearly all retrospective
studies.
From clinical experience, ECMO ini-
tiation is rather easy and fast, and ECMO
is a very eﬀective tool for enhancing and
ensuring systemic circulation and pro-
vide gas exchange. As such, it should be
primarily considered in patients with se-
vere acute cardiorespiratory failure (the
“crash and burn” patient). In addition,
some speciﬁc indications exist, such as
decompensated pulmonary arterial hy-
pertension and pulmonary embolism.
. Table 4 lists selected studies [67–72] of
VA-ECMO in cardiogenic shock.
From a pathophysiological perspec-
tive, VA-ECMO should be favored for
bridge-to-destinationorbridge-to-trans-
plantation, when recovery is not the pri-
mary goal and LVAD or transplantation
will follow. VA-ECMO is also favor-
able for bridge-to-surgery, especially for
embolectomy. In resuscitated patients
VA-ECMO is the commonly used de-
vice for bridge-to-decision. By contrast,
VA-ECMOmay not be the ideal support
form for isolated LV dysfunction with
potential for recovery (acute myocardial
infarction, myocarditis, Takotsubo syn-
drome, etc.), since afterload increases
and recovery may be hampered [53].
Of note, these are considerations from
daily clinical routine and pathophysiol-
ogy, but dedicated studies are urgently
needed to prospectively compare the dif-
ferent support forms. One such study
is the prospective, open-label, multicen-
ter, randomized, controlled “ANCHOR”
trial (Assessment of ECMO inAcuteMy-
ocardial Infarction with Non-reversible
Cardiogenic Shock to Halt Organ Fail-
ure and Reduce Mortality), which is cur-
rently investigating the use of ECMO in
cardiogenic shock during myocardial in-
farction. In this context, an interesting
tool that is already mentioned in cur-
rent heart failure guidelines [31] is the
“SAVE” score to estimate theprognosis of
patients with cardiogenic shock on VA-
ECMO [73]. Another promising score is
the “ENCOURAGE” score [72].
VA-ECMO for extracorporeal
resuscitation
. Table 5 lists a selection of studies
[74–86] on extracorporeal CPR (ECPR),
i. e., ECMO for refractory resuscitation.
Of note, to date there is no prospec-
tive randomized study on ECMO for
this indication, also for ethical reasons.
A comprehensive review of retrospective
studies has been recently published else-
where [87]. Taken together, the available
literature on ECPR suggests that ECMO
is suﬃcient toensure systemic circulation
in refractory arrest. However, mortality
varies between centers, and four factors
appear to critically determine ECPR suc-
cess: patient selection criteria, a detailed
standard operating procedure, immedi-
ate and suﬃcient bystander CPR, and
time from arrest to ECMO.. Table 6 lists
a proposal for inclusion and exclusion
criteria for ECPR. Of note, such criteria
can only set a frame for decision, but
may need to be adjusted for individual
patients. A standard operating proce-
dure for ECPR needs to incorporate all
elements from circulatory arrest and
bystander CPR over professional CPR,
early contact with the ECMO center,
team approach by anesthesiologists, car-
diologists, and intensivists, high-level
intensive care medicine, and optimal re-
habilitation. A proposal for a prospective
study considering all these factors has re-
cently been published [88]. The time-to-
ECMO interval is consistently associated
with mortality [78, 84], very likely due
to the increased incidence and severity
of post-resuscitation metabolism with
delayed extracorporeal support. Thus,
a dedicated program for ECPR needs
to put all eﬀorts into earliest ECMO
implantation and optimal preclinical
CPR.
Conclusion
Mechanical support is increasingly used
in cardiogenic shock to minimize or
avoid catecholamines and to facilitate
regeneration of the diseased heart. Re-
fractory cardiac arrest is an emerging
indication for mechanical support, and
recently more centers have developed
ECPR programs. Cardiogenic shock and
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Table 6 Proposed criteria for extracorporeal CPR (ECPR)




No ROSC after 10 min of professional CPRb
Exclusion criteria (one criterion is suﬃcient)
Severe comorbidity (cancer, end-stage liver cirrhosis, etc.)
Preexisting cognitive impairment/brain damage
Preclinical CPR >1hc
Optional exclusion criteria
pH at baseline <6.8
Lactate at baseline >15 mmol/l
Exceptions for criteria above
Accidental hypothermia
CPR cardiopulmonary resuscitation, ECMO extracorporeal membrane oxygenation
aAge limit depends on comorbidities and biological age
bExcellent CPR until ECMO is an essential prerequisite for success
cMay be extended in single cases, when very young patients need time for transfer and have optimal
CPR
arrest share many pathophysiological
features, and in this context VA-ECMO
is a powerful extracorporeal life support
system, as long as it is initiated early.
VA-ECMO use requires a dedicated
bridging strategy, such as bridge-to-re-
covery, bridge-to-decision, or bridge-to-
destination, and complications need to
be anticipated. Retrograde ﬂow support
increases LV afterload and may result in
LV distension, which can be prevented
and resolved by LV venting or active
LV unloading. Prospective controlled
studies are needed to develop speciﬁc
protocols for deﬁned clinical conditions,
in order to ﬁnd the optimal mechanical
support strategy in a given situation.
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Steigerung auf hohem Niveau
Deutscher Herzbericht 2016
Der Herzbericht stellt der deutschen
Herz-Medizin ein gutes Zeugnis aus.
Zwar zeigen die Statistiken, dass
Herzerkrankungen weiter zu den
häufigsten Gründen für eine Kran-
kenhausaufnahme zählen, jedoch
überleben immer mehr Betroffene.
„Noch 1990 starben 324,8 von 100.000
Einwohnern an den häuﬁgsten Herzerkran-
kungen, 2014 waren es 256,1“, erklärt der
Präsident der Deutschen Gesellschaft für
Kardiologie, Prof. Dr. Hugo Katus (Unikli-
nikum Heidelberg). „Dieser Rückgang um
21,15 % dokumentiert auf eindrucksvolle
Weise den Stellenwert und die Fortschritte
der deutschen Herz-Medizin.“
Angeführt wird die Statistik von Krankhei-
ten, die auf angeborene Fehlbildungen
zurückgehen. Im Vergleich zu 1990 ging
die Zahl der dadurch bedingten Todes-
fälle pro 100.000 Einwohner (Sterbeziﬀer)
um 66,67 % zurück. Es folgen die beiden
häuﬁgsten Herzerkrankungen: An einer
Herzinsuﬃzienz starben 2014 um 33,05 %
weniger Patienten als 1990, bei Patienten
mit koronaren Herzerkrankungen (Angina
Pectoris, Herzinfarkt) um 31,02 %. „We-
gen der Erkrankungshäuﬁgkeit haben die
Entwicklungen bei diesen beiden Krank-
heitsbildern wesentlich zur reduzierten
Gesamt-Sterblichkeit bei Herzerkrankun-
gen beitragen“, so Prof. Katus.
„Besonders erfreulich ist, dass selbst auf
hohem Niveau noch Verbesserungen er-
zielt werden konnten,“ zieht Prof. Katus
Bilanz. So zeigt sich, dass die Sterbeziﬀer
der häuﬁgsten Herzkrankheiten 2014 um
4,76 % unter dem Wert von 2013 liegt –
ein Trend, der sich bei nahezu allen Er-
krankungsformen zeigt: Bei Fehlbildungen
sank die Sterbeziﬀer von 2013 auf 2014 um
16,67 %, bei den koronaren Herzerkran-
kungen um 6,46%, bei Herzinsuﬃzienz um
3,17 % und bei den Rhythmusstörungen
um 2,16 %. Lediglich bei den Herzklappen-
Krankheiten blieb die Sterbeziﬀer mit 19,7
bzw. 19,8 praktisch konstant.
Quelle: Deutscher Herzbericht /
Deutsche Gesellschaft für Kardiologie
Weitere Infos: www.dgk.org
Berlin/Düsseldorf, 25.1.2017
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